Aerie Pharmaceuticals, Inc.

Duke University

Other

Novaer Holdings, Inc.

Cayman Chemical Company Incorporated

Merz North America, Inc.

Olsen, Elise

Mitchell Anthony deLong

Jill Marie Sturdivant

Susan Marie Royalty

Casey Kopczynski

Cheng-Wen Lin

Geoffrey Richard Heintzelman

Cynthia L Lichorowic

John McMillan McIver

Robert Scott Youngquist

Andriy Kornilov

Gilles Chambournier

Ramesh Krishnamoorthy

Elise A Olsen

Eric Carlson

John August Wos

Victor Fedij

Kalla Lynn Kvalnes

Raymond Boissy

Michael G Pamment

Biswanath De

Eric John Toone

Allen E Eckhardt

Yili Wang

Thomas E Richardson

Brian H Heasley

Marcos Sznaidman

David Lindsey Soper

Robert H Oakley

Michael Robert Peel

David L Epstein

Jack Snyder Amburgey, Jr

Haiyan George Dai

Jeffrey David Yingling

Xin Chen

Christine Hudson

Heeren Gordhan

Pratap Challa

Phillip W Snyder

Claire Louise Murray

Byappanahally N Narasinga Rao

Paresma R Patel

Provided herein are arylcyclopropyl amino-isoquinoline amide compounds. In particular, the disclosure provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the disclosure are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, diseases characterized by abnormal growth, such as cancers, and inflammatory diseases. The disclosure further provides compositions containing isoquinoline amide compounds.

Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Provided herein are amino isoquinolinyl amide and sulfonamide compounds that affect the function of kinases and other proteins in a cell and that are useful as therapeutic agents. In particular, these compounds are useful in the treatment of eye diseases such as glaucoma and retinal diseases, as anti-inflammatory agents, for the treatment of cardiovascular diseases, and for diseases characterized by abnormal growth, such as cancers.

The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.

Ophthalmic compositions

Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein.

Isoquinoline-steroid conjugates and uses thereof

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

Dual mechanism inhibitors for the treatment of disease

Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

Combination therapy

Compositions for treating glaucoma or reducing intraocular pressure

Provided herein are 8-methyl-8-azabicyclo[3.2.1]octan-3-yl and pyridin-4-ylmethanyl ester and amide compounds and compositions. Also provided herein are methods of preventing or delaying the onset of myopia in a subject in need thereof, comprising administering the compounds or compositions provided herein to the subject. Also provided herein are methods of reducing or preventing the progression of myopia in a subject in need thereof, comprising administering the compounds or compositions provided herein to the subject.

Compounds, compositions and methods for treatment of myopia

Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds

Growing community of inventors

Chapel Hill, NC, United States of America

Mitchell Anthony deLong